SAN DIEGO, Aug. 13, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
technologies designed to provide physicians with clinically
actionable information to improve outcomes, announces it has
entered into an agreement with a healthcare group to provide
COVID-19 testing to skilled nursing facilities. The group
operates and supports more than 50 facilities in multiple states,
with most located in California,
the state with one of the most stringent COVID-19 testing
regulations in the U.S.
"We began by providing COVID-19 testing services to a few
facilities within this group, and they have been impressed by our
quick turnaround times, with the vast majority of our COVID-19
testing results reported within 48 hours," said Michael Nall, President and CEO of
Biocept. "They have also been pleased with our attentive
customer service, test quality and on-line reporting
capabilities. Our initial service has now expanded into a
formal agreement for Biocept to be one of only two labs contracted
to provide COVID-19 testing to employees and residents/patients in
this system. We expect that COVID-19 testing volume performed
by Biocept for this agreement will vary depending on COVID-19
positivity rates as facilities are required to continue to serially
test when one test comes back as positive."
Several of the skilled nursing facilities have implemented
Biocept's cutting-edge, new online ordering system for ease-of-use
to customers. Biocept's new systems makes COVID-19 test
ordering efficient for clients and streamlines the front-end
onboarding process within Biocept's CLIA laboratory, allowing
increased testing capacity and decreased costs. Biocept
believes its test performance, quality and customer service are
ideal for supporting healthcare facilities to care for their
residents and patients as they stay compliant with state
mandates.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In addition,
Biocept recently added COVID 19 testing to support efforts to fight
the pandemic. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding the ability of Biocept's tests to provide
clinically actionable information to oncologist and their patients,
the suitability of Biocept's test performance, quality and customer
service for supporting healthcare facilities, and the ability of
Biocept's platform to identify cancer mutations and alterations to
inform physicians about a patient's disease and therapeutic
options, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in Biocept's
Securities and Exchange Commission (SEC) filings. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
http://www.sec.gov/.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-announces-agreement-with-healthcare-group-to-provide-covid-19-testing-to-multi-state-locations-301111599.html
SOURCE Biocept, Inc.